Evidence map›Paper›PMID 34534382›Full record

ReviewCancer science2021

Emerging treatment evolutions and integrated molecular characteristics of biliary tract cancers.

Ruyi Zhang, Marco Puzzoni, Stefano Mariani, Yi Zheng, Nicole Liscia, Yixuan Guo, Clelia Donisi, Yu Liu, Valentino Impera, Weijia Fang and 1 more

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancer science, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Ruyi ZhangDepartment of Medical Oncology, School of Medicine, The First Affiliated Hospital, Zhejiang University, Hangzhou, China.
Marco PuzzoniDepartment of Medical Oncology, Medical Oncology, University Hospital of Cagliari, University of Cagliari, Cagliari, Italy.
Stefano MarianiDepartment of Medical Oncology, Medical Oncology, University Hospital of Cagliari, University of Cagliari, Cagliari, Italy.
Yi ZhengDepartment of Medical Oncology, School of Medicine, The First Affiliated Hospital, Zhejiang University, Hangzhou, China.
Nicole LisciaMedical Oncology Unit, Sapienza University of Rome, Rome, Italy.
Yixuan GuoDepartment of Medical Oncology, School of Medicine, The First Affiliated Hospital, Zhejiang University, Hangzhou, China.
Clelia DonisiDepartment of Medical Oncology, Medical Oncology, University Hospital of Cagliari, University of Cagliari, Cagliari, Italy.
Yu LiuDepartment of Medical Oncology, School of Medicine, The First Affiliated Hospital, Zhejiang University, Hangzhou, China.
Valentino ImperaMedical Oncology Unit, Sapienza University of Rome, Rome, Italy.
Weijia FangDepartment of Medical Oncology, School of Medicine, The First Affiliated Hospital, Zhejiang University, Hangzhou, China.ORCID https://orcid.org/0000-0001-9849-347X
Mario ScartozziDepartment of Medical Oncology, Medical Oncology, University Hospital of Cagliari, University of Cagliari, Cagliari, Italy.
First Affiliated Hospital Zhejiang University · CNUniversity of Cagliari · ITSapienza University of Rome · IT

Funding

National Major Scientific and Technological Special Project for Significant New Drugs Development during the Thirteenth Five-year Plan Period 2020ZX 09201-003
6 · The paper itself

Abstract

Biliary tract cancers (BTCs) consist of a group of highly heterogeneous malignancies that are characterized by genomic differences among tumors from different anatomic sites. The current treatment for BTC includes surgery, chemotherapy, target therapy, and immunotherapy. Although surgery remains the primary option for localized disease, representing the only potential curative treatment, a high risk of recurrence cannot be neglected. Chemotherapy has been considered the standard of care for both advanced and metastatic disease and in adjuvant settings. However, drug resistance is a major obstacle associated with chemotherapy. The development of genetic testing technologies, including next-generation sequencing, has opened the door for the identification of drug targets and candidate molecules. A series of preclinical studies has demonstrated the role of gene mutations, abnormal signaling pathways, and immunosuppression in the pathogenesis of BTC, laying the foundation for the application of targeted therapy and immunotherapy. A variety of molecularly targeted agents, including pemigatinib, have shown promising survival benefits in patients with advanced disease. The rapidly evolving role of multimodal therapy represents the subject of this review.

Indexed as

Gene Regulatory NetworksAntineoplastic AgentsBiliary Tract NeoplasmsClinical Trials as TopicCombined Modality TherapyDigestive System Surgical ProceduresHumansMolecular Targeted TherapyPrecision MedicineRadiotherapyAntineoplastic Agentsbiliary tract cancersclinical trialsimmunotherapymolecular characterizationtargeted therapy

Identifiers

PMID34534382
PMCPMC8645726
OpenAlexW3199473218

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.